FIELD: medicine.
SUBSTANCE: what is presented is using a complex of tris-(2-hydroxyethyl)amine with bis-(2-methylphenoxy-acetate)zinc[zincatran or citrimine] of formula: (HOCH2CH2)3N·Zn(OOCCH2OC6H4CH3-2)2 as an acidic phospholipase Al inhibitor.
EFFECT: invention enables extending the substance use as a component of new pharmacological preparations for preventing sclerotic involvement of blood vessels.
1 tbl
Title | Year | Author | Number |
---|---|---|---|
USING COMPLEX OF TRIS-(2-HYDROXYETHYL)AMINE AND ZINC BIS-(2-METHYLPHENOXYACETATE) (CINKATRAN) AS AGENT SUPPRESSING TOTAL ACTIVITY OF BASIC (ALKALINE) MONONUCLEAR PHOSPHOLIPASE A2 | 2014 |
|
RU2546537C1 |
METHOD OF ATHEROGENESIS CORRECTION IN EXPERIMENT USING 1-(GERMATRAN-1-YL)-1-OXYETHYLAMINE | 2020 |
|
RU2741906C1 |
USE OF 1-(GERMATRAN-1-YL)-1-HYDROXYETHYLAMINE FOR INHIBITING THE DEVELOPMENT OF ATHEROSCLEROSIS IN THE EXPERIMENT | 2020 |
|
RU2746321C1 |
METHOD FOR CORRECTING ATHEROGENESIS EXPERIMENTALLY USING 1-HYDROXYGERMATRANE | 2020 |
|
RU2741229C1 |
SUBSTANCE REDUCING CHOLESTEROL ESTERASE ACTIVITY | 2014 |
|
RU2540518C1 |
1-HYDROXYGERMATRANE USAGE FOR INHIBITING THE DEVELOPMENT OF ATHEROSCLEROSIS IN THE EXPERIMENT | 2020 |
|
RU2742972C1 |
AGENT MODULATING ACID PHOSPHOLIPASE A1 ACTIVITY | 2010 |
|
RU2445087C1 |
USING COMPLEX OF TRIS-(2-HYDROXYETHYL)AMINE AND ZINC BIS-(2-METHYLPHENOXY-ACETATE) (ZINCATRAN) AS HYPOLIPIDEMIC (ANTIATHEROSCLEROTIC) AGENT | 2014 |
|
RU2575788C1 |
AGENT TO DECREASE CHOLESTEROL ESTERASE ACTIVITY | 2010 |
|
RU2444357C1 |
WORKING ABILITY IMPROVEMENT | 2014 |
|
RU2540476C1 |
Authors
Dates
2015-04-10—Published
2014-03-27—Filed